Confidence In Factor XIa Inhibition Wavers After Bristol/Janssen And Bayer Data

High Expectations For Next Big Oral Anticoagulant Drug Class

BMS/Janssen’s milvexian and Bayer’s asundexian prevented strokes without major increases in severe bleeding and no fatal bleeds but Phase III outcomes are uncertain based on mixed Phase II data.

Red question mark on a background of black question marks
Phase II trials left several unanswered questions for milvexian and asundexian • Source: Shutterstock

Factor XIa inhibition is a new oral anticoagulant drug class that carries the promise of protecting patients from strokes without the higher risk of bleeding associated with predecessor drugs, the blockbuster Factor Xa inhibitors. However, new Phase II data for the two most advanced oral Factor XIa inhibitors – milvexian from Bristol Myers Squibb Company/Janssen Pharmaceutical Cos. and Bayer AG’s asundexian – raise new questions about the drugs’ future.

BMS and Janssen, a Johnson & Johnson company, reported results from the Phase II AXIOMATIC-SSP clinical trial evaluating multiple...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By 

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By 

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D